Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia

By Walker Alison R.   Klisovic Rebecca B.   Garzon Ramiro   Schaaf Larry J.   Humphries Kristina   Devine Steven M.   Byrd John C.   Grever Michael R.   Marcucci Guido   Blum William  

Leukemia and Lymphoma, Vol. 55, Iss. 6, 2014-06 ,pp. : 1304-1308

Informa Healthcare

Access to resources Recommend Favorite

Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia

By Klisovic Rebecca B.   Blum William   Liu Zhongfa   Xie Zhiliang   Kefauver Cheryl   Huynh Lenguyen   Zwiebel James A.   Devine Steven M.   Byrd John C.   Grever Michael R.   Chan Kenneth K.   Marcucci Guido  

Leukemia and Lymphoma, Vol. 55, Iss. 6, 2014-06 ,pp. : 1332-1336

Informa Healthcare

Access to resources Recommend Favorite

High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study

By Tedeschi Alessandra   Montillo Marco   Strocchi Elena   Cafro Anna   Tresoldi Elisabetta   Intropido Liliana   Nichelatti Michele   Marbello Laura   Baratè Claudia   Camaggi Carlo   Morra Enrica  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 6, 2007-06 ,pp. : 771-779

Springer Publishing Company

Access to resources Recommend Favorite

Elacytarabine (CP-4055) in the treatment of acute myeloid leukemia

By DiNardo Courtney D   O'Brien Susan   Gandhi Varsha V   Ravandi Farhad  

Future Oncology, Vol. 9, Iss. 8, 2013-08 ,pp. : 1073-1082

Future Medicine

Access to resources Recommend Favorite

Clofarabine for the treatment of adult acute myeloid leukemia

By Thomas Xavier   Raffoux Emmanuel   Elhamri Mohamed   Lobe Ida   Cannas Giovanna   Dombret Hervéé  

Future Oncology, Vol. 5, Iss. 8, 2009-10 ,pp. : 1197-1210

Future Medicine

Access to resources Recommend Favorite